NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-18-496 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
Funding Opportunity PAR-18-494 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.
Funding Opportunity RFA-AT-18-003 from the NIH Guide for Grants and Contracts. Evidence is building that low molecular weight compounds, derived from interaction of dietary constituents and other natural products with the microbiome, have important biological activity in animal models. This initiative seeks to characterize the compounds produced by microbial metabolism of dietary phytochemicals, identify the commensal bacteria responsible for their production and establish the biological signatures that define their interaction with a biological system.
Funding Opportunity PAR-18-432 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person-months effort (25% effort) in any year of the R00 phase.
Funding Opportunity PAR-18-515 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.
Funding Opportunity PAR-18-501 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research.
Funding Opportunity RFA-HL-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to study the normal biological aging process in the human lungs; specifically focusing on a) changes in molecular hallmarks of aging and b) building a dynamic molecular map of aging in the lung that can be used as a reference for researchers to better define the mechanisms of age-related lung diseases.
Notice NOT-NS-18-022 from the NIH Guide for Grants and Contracts
Notice NOT-ES-18-003 from the NIH Guide for Grants and Contracts
Notice NOT-ES-18-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Notice NOT-ES-18-005 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-002 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-028 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-117 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-18-014 from the NIH Guide for Grants and Contracts. This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-18-009). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.
Funding Opportunity RFA-HD-19-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage small businesses to collaborate with scientists and clinicians in the field of gynecologic health to develop, advance, and validate new devices and methods for non-invasive diagnosis of endometriosis, adenomyosis, and/or uterine fibroids. Projects supported will aim to shorten the time to diagnosis, decrease the invasiveness of current techniques, and/or improve accessibility, safety, convenience, and costs of diagnosis.
Funding Opportunity RFA-NS-18-018 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to develop new and improved perturbation technologies suitable for controlling specified cell types and circuits to modulate function in the central nervous system. This FOA seeks applications to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Development of new technologies and therapies, as well as of disease models are outside the scope of this FOA. However, activities related to combining multiple recording modalities are allowed. As part of this program, investigators will be required to participate in a consortium to develop standards and model systems for the evaluation of current and next generation neuromodulation technologies.
Notice NOT-NS-18-027 from the NIH Guide for Grants and Contracts
Notice NOT-FD-18-006 from the NIH Guide for Grants and Contracts